Stockscreener 앱 받기
13.00
7.08%
-0.99
시장 영업 전:
13.00
Maplight Therapeutics Inc 주식(MPLT)의 최신 뉴스
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Jefferies & Co Initiates Coverage on MapLight Therapeutics With Buy Rating, $32 Price Target - MarketScreener
Morgan Stanley Initiates MapLight Therapeutics at Overweight With $34 Price Target - MarketScreener
MPLT Analyst Forecasts - Quiver Quantitative
MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners - Investing.com Canada
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential - TipRanks
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials - TipRanks
MapLight Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MPLT | US56565P1030 - MarketScreener
MapLight Therapeutics stock initiated with Buy rating at Jefferies By Investing.com - Investing.com Canada
MapLight Therapeutics stock initiated with Buy rating by Stifel - Investing.com Canada
Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
MapLight Therapeutics, Inc. (MPLT) Balance Sheet - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Latest Press Releases & Corporate News - Yahoo! Finance Canada
MapLight Therapeutics, Inc. share price - Capital.com
Timothy John Garnett Net Worth (2025) - GuruFocus
Erin Pennock Foff Net Worth (2025) - GuruFocus
Anatol Kreitzer Net Worth (2025) - GuruFocus
Vishwas Setia Net Worth (2025) - GuruFocus
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More - AOL.com
MapLight Therapeutics, Inc. (MPLT) stock major holders - Yahoo Finance UK
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Maplight Therapeutics (MPLT) 10K Form and SEC Filings 2025 - MarketBeat
Maplight Therapeutics (MPLT) Stock Chart and Price History 2025 - MarketBeat
Evommune nabs $150M in IPO amid federal shutdown - BioPharma Dive
Maplight Therapeutics (MPLT) Competitors and Alternatives 2025 - MarketBeat
MapLight Therapeutics, Inc. (MPLT) Stock Major Holders - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) stock historical prices and data - Yahoo Finance UK
Operating cash flow per share of MapLight Therapeutics, Inc. – BOATS:MPLT - TradingView
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – BOATS:MPLT - TradingView
MapLight Therapeutics, Inc. Cash Flow – BOATS:MPLT - TradingView
MapLight Therapeutics, Inc. (MPLT) options chain - Yahoo Finance UK
Net current asset value per share of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
U.S. IPO Weekly Recap: Navan Slips, And Medline Joins The Pipeline To Close Out October - Seeking Alpha
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Major Investment Alert: A S Novo’s Multi-Million Dollar Bet on MapLight Therapeutics! - TipRanks
Drug developer Evommune to go public next week, following MapLight's successful IPO - The Business Journals
MapLight Therapeutics completes $296 million IPO on nasdaq - Investing.com
Inflammation biotech Evommune prices IPO after MapLight's $250M debut - Fierce Biotech
Catalyst4, Inc. Makes a Major Move with a Massive Stock Purchase in MapLight Therapeutics! - TipRanks
MapLight Therapeutics, Inc. (MPLT) Latest Stock News & Headlines - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Stock Forum & Discussion - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Interactive Stock Chart - Yahoo! Finance Canada
MapLight Therapeutics completes $296 million IPO on nasdaq By Investing.com - Investing.com Nigeria
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Benzinga
Cash from investing activities of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
MPLT Pivot Points, Technical Analysis and Moving AveragesMaplight Therapeutics Inc Technicals - CMLviz
MPLT Financial Statements & ChartsMaplight Therapeutics Inc MacroTrends - CMLviz
Price to earnings ratio of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
2.13%
4.32%
자본화:
|
볼륨(24시간):